Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atorvastatin - Pfizer

Next Previous
X
Search
Drug Profile

Atorvastatin - Pfizer

Alternative Names: Atorvastatin calcium; Cardyl; CI 981; Lipitor; Prevencor; Sortis; Tahor; Xarator 10; YM 548; Zarator

Latest Information Update: 20 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Parke-Davis
  • Developer Astellas Pharma; Laboratorios Phoenix; Pfizer; University of Rochester
  • Class Amides; Antihyperlipidaemics; Esters; Fatty acids; Fluorobenzenes; Heptanoic acids; Pyrroles; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Heart failure; Hypercholesterolaemia; Hyperlipoproteinaemia type IIa; Hyperlipoproteinaemia type III; Hypertriglyceridaemia; Low HDL cholesterol
  • No development reported Metabolic syndrome
  • Discontinued Alzheimer's disease; Neurological disorders; Veno-occlusive disorders

Most Recent Events

  • 14 Nov 2024 Atorvastatin receives for National Institute for Health and Care Excellence (NICE) recommendation for Cardiovascular disorders
  • 08 Apr 2021 Viatris terminates its marketing agreement with Astellas for Atorvastatin in Japan
  • 06 Jan 2020 No recent reports on development identified - Phase-I/II for Metabolic syndrome in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top